FDA Launches FAERS Public Dashboard for Cosmetic Products: Transparency in Adverse Event Reporting

On September 12, 2025, the U.S. Food and Drug Administration (FDA) introduced the FAERS Public Dashboard for Cosmetic Products, a new interactive platform designed to improve cosmetic safety monitoring and transparency. This tool gives real-time access to adverse event reports related to cosmetic products, helping consumers, regulators, and industry professionals better understand product safety trends.

What is the FAERS Dashboard for Cosmetic Products?

The FDA Adverse Event Reporting System (FAERS) Public Dashboard for Cosmetics is a web-based interactive tool that allows users to:

• Access daily updates on cosmetic adverse event reports.
• Search and filter results by product, event type, severity, or date.
• Download data for further analysis, market research, or compliance monitoring.

Reports in the dashboard include:

• Mandatory submissions from cosmetic manufacturers and responsible persons (as required under MoCRA 2022).
• Voluntary reports from consumers, health professionals, and salon practitioners.

👉 Access the official dashboard here: FDA FAERS Dashboard.

Why This Matters for Cosmetic Companies

The new FAERS dashboard marks a turning point for cosmetic safety oversight in the U.S.

1. Transparency and accountability: Safety issues are now visible to the public, creating reputational risks if adverse events accumulate.
2. Regulatory compliance: Companies must ensure timely and accurate reporting of serious adverse events to avoid non-compliance under MoCRA.
3. Market intelligence: Competitors’ safety data can now be tracked, offering insight into product categories under scrutiny.
4. Signal detection: Early warning of trends can support better risk assessments, labeling, and product reformulation decisions.

Key Limitations of the Dashboard

While powerful, the dashboard should be interpreted carefully:

• Reports are not verified by FDA and do not prove causality.
• Data may be incomplete or duplicated.
• True incidence rates cannot be calculated since usage volume (exposure data) is missing.

How Companies Should Respond

To adapt to this new environment, cosmetic companies should:

• Implement strong internal adverse event reporting systems.
• Monitor the FAERS dashboard regularly for their own brands and competitors.
• Train teams to analyze and interpret signals responsibly.
• Integrate dashboard findings into regulatory compliance strategies and safety substantiation processes.

Conclusion

The FDA’s FAERS Public Dashboard for Cosmetic Products represents a new era of transparency in cosmetic safety. For companies, this is not only a compliance obligation but also an opportunity to demonstrate responsibility, build consumer trust, and improve product safety strategies.

By proactively using the dashboard, businesses can stay ahead of potential risks while ensuring they meet their obligations under MoCRA.